How to Value a Gastroenterology (GI) Practice in 2026

Gastroenterology has become one of the most actively pursued physician specialties in private equity. Over the past five years, I've watched GI practice multiples climb from the 5-7x EBITDA range into territory that would have been unthinkable a decade ago — 10x, 12x, even 14x EBITDA for the right platform. The driver isn't complicated: endoscopy centers generate enormous recurring procedural revenue, and PE firms have figured out the playbook to consolidate them.

But the gap between a GI practice that owns its ambulatory surgery center and one that doesn't is staggering. If you're a GI physician thinking about your exit, understanding this distinction is worth millions.

The ASC Ownership Divide

Here's the single most important factor in GI practice valuation: do you own your endoscopy center? A four-physician GI practice collecting $6M annually with full ASC ownership might sell for $8-14M to a PE platform. That same practice without an ASC — referring colonoscopies and EGDs to a hospital outpatient department — might sell for $3-5M. Same physicians, same patient volume, potentially triple the valuation.

The math is straightforward. A busy GI physician performs 1,500-2,500 endoscopic procedures per year. At an average facility fee of $1,200-1,800 per procedure (colonoscopy reimbursement varies by payer, but Medicare alone pays roughly $500 for the facility component), a four-doc group doing 7,000 procedures generates $8-12M in facility fees alone. That revenue has 50-65% margins in a well-run ASC. When a PE firm looks at a GI practice, they're really buying the ASC cash flow with physicians attached.

Practices with partial ASC ownership — say a 40-60% stake in a multi-specialty ASC — fall in between. I've seen these valued at 6-9x EBITDA depending on the ownership percentage, governance rights, and whether there's a path to increasing the stake.

Who's Buying GI Practices (and What They Pay)

The GI consolidation wave is dominated by a handful of platforms that have raised billions specifically for this specialty.

• US Digestive Health (backed by Amulet Capital) has assembled 60+ practice locations and is one of the most aggressive acquirers, typically paying 8-12x EBITDA for platform-quality groups with ASC ownership.
• GI Alliance (backed by Apollo Global Management) is the largest GI platform in the country with 800+ providers across 15+ states. Their bolt-on multiples run 6-9x EBITDA, with higher multiples for groups that fill geographic gaps.
• PE One Gastroenterology and several newer entrants are competing for mid-size groups (4-10 physicians), often paying 7-10x EBITDA to build regional density.

For comparison, a GI practice selling to another physician group in a private transaction — no PE involvement — typically trades at 4-6x EBITDA or 60-80% of collections, consistent with broader medical practice valuation benchmarks. The PE premium exists because platforms monetize ASC economics at scale in ways individual groups cannot.

Key Metrics That Drive GI Practice Value

Beyond ASC ownership, buyers scrutinize several GI-specific metrics that most practice owners don't think about until they're in due diligence.

Procedure volume per physician. A productive GI doc performs 2,000+ scoping procedures per year. Below 1,200, buyers question utilization. Above 2,500, they worry about burnout risk and quality metrics. The sweet spot is 1,500-2,200 per physician, which signals healthy demand without over-reliance on any single provider.

Anesthesia model.Practices using CRNAs (nurse anesthetists) for procedural sedation have significantly better ASC economics than those using anesthesiologist-directed MAC (monitored anesthesia care). CRNA-staffed endoscopy centers save $300-500 per case in anesthesia costs. Buyers will model this into their valuation — a group doing 7,000 cases/year with a CRNA model is generating $2-3.5M more in margin than the same group using MAC.

Pathology capture.GI practices that have an in-house pathology arrangement or own a share of a pathology lab capture an additional $150-300 per colonoscopy in specimen processing fees. On 7,000 procedures, that's $1-2M in ancillary revenue that flows straight to the bottom line.

Payer mix.Commercial payers reimburse colonoscopies at 2-4x Medicare rates for the facility fee. A practice in a market with 60%+ commercial payer mix is dramatically more valuable than one in a Medicare-heavy population. I've seen this single factor create a 2-3x difference in ASC profitability between otherwise identical practices.

Provider count and age distribution.PE buyers are buying future cash flow. If three of your four partners are over 60 and planning to retire within five years, the buyer faces a massive recruitment and retention problem. Groups with a balanced age distribution — a mix of senior partners and physicians in their 40s — command meaningfully higher multiples because the cash flows are more durable.

The Endoscopy Center Economics

Understanding ASC financials is essential because they represent the majority of value in most GI practice transactions. A typical two-room endoscopy center supporting 4-6 GI physicians generates $4-8M in annual revenue with EBITDA margins of 45-60%. Development cost for a de novo ASC runs $2-4M depending on the market and build-out requirements.

The key operational metrics buyers analyze include cases per room per day (target: 12-16 colonoscopies), room turnover time (under 15 minutes is best-in-class), and complication rates. CMS quality measures — adenoma detection rate above 25%, cecal intubation rate above 95% — aren't just clinical metrics. They're increasingly tied to payer contracts and reimbursement levels, making them direct valuation inputs.

As part of ASC valuation more broadly, GI-focused centers are among the most valuable because of high procedure volume, short case times, and low complication rates — all of which translate to predictable, high-margin cash flow.

Deal Structure: What "12x EBITDA" Actually Means

When a PE platform offers 12x EBITDA for a GI practice, that headline number rarely represents all cash at closing. Typical deal structures in GI include:

• 60-70% cash at close— the upfront payment, usually funded by the PE firm's equity and leveraged debt.
• 10-20% in equity rollover— you reinvest a portion of your proceeds into the new platform entity. This is where the "second bite of the apple" comes from when the platform sells to the next PE buyer in 4-6 years.
• 10-20% in earn-outs or holdbacks— tied to physician retention, revenue targets, or EBITDA milestones over 2-3 years.

A $10M deal at "12x EBITDA" might actually be $6.5M cash, $2M in equity rollover, and $1.5M in earn-outs. That's still an excellent outcome, but the effective cash multiple is closer to 8x. Always model the present value of the total consideration, not the headline number.

Maximizing Your GI Practice Value Before Sale

If you're 2-3 years out from an exit, the highest-ROI moves for GI practices are:

Develop or acquire ASC ownership.If you're still performing procedures at a hospital, explore developing a freestanding endoscopy center or acquiring a stake in an existing one. The lift from zero ASC ownership to full ownership can double or triple your practice valuation. Yes, it requires $2-4M in capital, but the payoff at exit is enormous.

Recruit younger physicians.Every physician under 45 you add to the group extends the practice's productive life and directly increases the multiple a PE buyer will pay. A group of six with an average age of 48 is far more attractive than a group of four with an average age of 58.

Optimize your anesthesia model.Transitioning from anesthesiologist-directed MAC to a CRNA model can add $300-500 per case to your ASC margins. On 7,000 annual cases, that's $2-3.5M in additional EBITDA — which at an 8x multiple means $16-28M in incremental enterprise value.

Capture ancillary revenue. Pathology, infusion therapy (for IBD biologics like Remicade and Entyvio), and clinical research all create revenue streams that PE buyers value highly because they increase per-patient economics.

The Bottom Line

GI practice valuation is really two stories. Without an ASC, you're selling a physician services business at 4-7x EBITDA — respectable, but not life-changing for a multi-partner group. With ASC ownership, you're selling a procedural revenue machine at 8-14x EBITDA, and the current healthcare M&A environment has PE firms competing aggressively for these assets. The physicians I've seen capture the most value are the ones who recognized this dynamic early, invested in ASC ownership, built a balanced provider team, and went to market with clean financials and a clear growth story.